Science SignalingBiochemistryPeer-reviewed journal article
Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminib
Serena MuratcioğluiD, Christopher A. EideiD, Chien‐Lun HungiD, Kent GordayiD, Emily SumpenaiD, Wenqi ZuoiD, Jay T. GrovesiD, Brian J. DrukeriD, John KuriyaniD
Abstract
Chromosomal translocations that fuse the ABL1 gene to BCR and TEL cause human leukemias. Oligomerization and the loss of an inhibitory myristoylation modification lead to unregulated kinase activity of the BCR-ABL and TEL-ABL fusion proteins. ATP-competitive ABL inhibitors, such as imatinib and ponatinib, are effective against both fusion proteins. We discovered that asciminib, an allosteric inhibitor of BCR-ABL that binds to the myristoyl binding site in the ABL kinase domain, is >2000-fold less potent against TEL-ABL than BCR-ABL in cell-growth assays. This is surprising because the ABL components of the two fusion proteins, including the asciminib binding sites, have identical sequence. We deleted a short helical segment in the ABL kinase domain that closes over asciminib when it is bound. This deletion results in asciminib resistance in BCR-ABL, but has no effect on TEL-ABL, suggesting that the native autoinhibitory mechanism that asciminib engages in BCR-ABL is disrupted in TEL-ABL. We show, using mammalian cell expression and single-molecule microscopy, that BCR-ABL is mainly dimeric while TEL-ABL forms higher-order oligomers. Oligomerization can promote trans-autophosphorylation of ABL, and we find that a regulatory phosphorylation site in the SH3 domain of ABL (Tyr 89) is highly phosphorylated in TEL-ABL. This phosphorylation is expected to disassemble the autoinhibited conformation of ABL, thereby preventing asciminib binding. We show that TEL-ABL is intrinsically susceptible to inhibition by asciminib, but that increased phosphorylation results in resistance. Our results demonstrate that different ABL fusion proteins can have dramatically different responses to allosteric inhibitors due to differential phosphorylation. One Sentence SummaryWhen TEL-ABL is phosphorylated, it is insensitive to asciminib. However, when TEL-ABL is dephosphorylated by a phosphatase, asciminib sensitivity is restored.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 3
- FWCI
- 2.15
- Field percentile
- top 12%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The STAMP inhibitor asciminib is a new treatment option for ABL-rearranged ALL revealing a novel role for the 5' fusion partner in determining drug response
Laura N Eadie, Daniel P. McDougal, … Deborah L. White·bioRxiv·May 6, 2025
- Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistance
A. Lyczek, B.-T. Berger, … M. A. Seeliger·bioRxiv·Jun 28, 2021
- The molecular basis of Abelson kinase regulation by its αI-helix
J. Paladini, A. Maier, … S. Grzesiek·bioRxiv·Oct 4, 2023
- Proximity-induced rewiring of oncogenic kinase triggers apoptosis
Manuel L. Merz, Veronika M. Shoba, … Amit Choudhary·ACS Central SciencePeer-reviewed·Apr 9, 2026
- De novo linear phosphorylation site motifs for BCR-ABL kinase revealed by phospho-proteomics in yeast
Martin Smolnig, Sandra Fasching, Ulrich Stelzl·Journal of Proteome ResearchPeer-reviewed·Apr 13, 2023
- RAPSYN-Mediated Neddylation of BCR-ABL Alternatively Determines the Fate of Philadelphia Chromosome-positive Leukemia